Haemonetics (NYSE:HAE) Price Target Raised to $90.00 at Mizuho

Haemonetics (NYSE:HAE) had its target price raised by Mizuho from $85.00 to $90.00 in a report released on Wednesday morning,Benzinga reports. They currently have an outperform rating on the medical instruments supplier’s stock.

Several other research firms have also weighed in on HAE. Bank of America raised Haemonetics from a “neutral” rating to a “buy” rating and raised their price objective for the company from $72.00 to $80.00 in a research note on Friday, May 22nd. Robert W. Baird set a $67.00 target price on shares of Haemonetics in a report on Friday, May 8th. Wall Street Zen upgraded shares of Haemonetics from a “hold” rating to a “buy” rating in a research note on Saturday, May 23rd. Citigroup reaffirmed a “neutral” rating on shares of Haemonetics in a report on Wednesday, July 8th. Finally, Barrington Research lowered their price objective on shares of Haemonetics from $94.00 to $89.00 and set an “outperform” rating for the company in a research report on Tuesday, May 12th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the company. According to MarketBeat, Haemonetics has a consensus rating of “Moderate Buy” and a consensus target price of $78.89.

Haemonetics Trading Up 3.3%

HAE opened at $76.83 on Wednesday. The stock has a market capitalization of $3.49 billion, a price-to-earnings ratio of 38.03, a P/E/G ratio of 1.50 and a beta of 0.52. The company has a quick ratio of 1.87, a current ratio of 2.95 and a debt-to-equity ratio of 1.53. Haemonetics has a twelve month low of $47.31 and a twelve month high of $87.32. The company has a 50-day simple moving average of $69.55 and a 200 day simple moving average of $66.18.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 EPS for the quarter, beating the consensus estimate of $1.28 by $0.01. The firm had revenue of $346.35 million for the quarter, compared to analyst estimates of $336.83 million. Haemonetics had a net margin of 7.29% and a return on equity of 27.30%. The business’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same period last year, the firm earned $1.24 EPS. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. Analysts predict that Haemonetics will post 5.21 EPS for the current fiscal year.

Institutional Investors Weigh In On Haemonetics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Kemnay Advisory Services Inc. bought a new position in Haemonetics during the fourth quarter worth $26,000. True Wealth Design LLC boosted its position in Haemonetics by 6,700.0% during the fourth quarter. True Wealth Design LLC now owns 340 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 335 shares during the last quarter. Leonteq Securities AG acquired a new stake in Haemonetics during the 4th quarter worth about $30,000. EverSource Wealth Advisors LLC grew its holdings in Haemonetics by 2,640.0% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock worth $31,000 after acquiring an additional 396 shares during the period. Finally, Kestra Advisory Services LLC bought a new position in shares of Haemonetics in the 4th quarter worth about $34,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.